News and Announcements
Coinmat receives further prominent access to the Board of Directors
- Published August 22, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Dr Sothy Kol-Men advises banks, fund managers and fintechs in DLT, digital assets, blockchain and fund regulation issues. He has many years of management experience and was, among other things, CEO of a fund manager of a banking group based in Switzerland and Liechtenstein.
He is an experienced strategy and regulatory expert with a deep understanding of capital markets, regulatory issues, crypto assets and securities tokens.
Currently, Sothy is a member of the board of directors and advisor to various fintech companies in Switzerland and Liechtenstein. He is also President of the SACA (Swiss Asia Crypto Alliance).
He holds a doctorate in law and is a graduate of the University of Liechtenstein. His doctoral thesis deals with the regulation of alternative investment funds in Liechtenstein.
About Coinmat AG
Coinmat® is the world’s first crypto ATM operator with a full financial license. With a self-developed cash flow transaction service (CTS), Coinmat is able to realize for the first time in the industry a complete functionality regarding the payment and withdrawal of cash for the customers of the crypto ATMs. As a first mover, Coinmat is ready for Blitzscaling.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
